Abstract:The continual spread of novel coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), posing a severe threat to the health worldwide. The main protease (M-pro, alias 3CL(pro)) of SARS-CoV-2 is a crucial enzyme for the maturation of viral particles and is a very attractive target for designing drugs to treat COVID-19. Here, we propose a multiple conformation-based virtual screening strategy to discover inhibitors that can target SARS-CoV-2 M-pro. Based on this strategy, nine M-pro structures and a protein mimetics library with 8960 commercially available compounds were prepared to carry out ensemble docking for the first time. Five of the nine structures are apo forms presented in different conformations, whereas the other four structures are holo forms complexed with different ligands. The surface plasmon resonance assay revealed that 6 out of 49 compounds had the ability to bind to SARS-CoV-2 M-pro. The fluorescence resonance energy transfer experiment showed that the biochemical half-maximal inhibitory concentration (IC50) values of the six compounds could hamper M-pro activities ranged from 0.69 +/- 0.05 to 2.05 +/- 0.92 mu M. Evaluation of antiviral activity using the cell-based assay indicated that two compounds (Z1244904919 and Z1759961356) could strongly inhibit the cytopathic effect and reduce replication of the living virus in Vero E6 cells with the half-maximal effective concentrations (EC50) of 4.98 +/- 1.83 and 8.52 +/- 0.92 mu M, respectively. The mechanism of the action for the two inhibitors were further elucidated at the molecular level by molecular dynamics simulation and subsequent binding free energy analysis. As a result, the discovered noncovalent reversible inhibitors with novel scaffolds are promising antiviral drug candidates, which may be used to develop the treatment of COVID-19.

Novel nucleocapsid protein-targeting phenanthridine inhibitors of SARS-CoV-2

Discovery of Peptidomimetic Spiropyrrolidine Derivatives As Novel 3clpro Inhibitors Against SARS-CoV-2

Structure-Based Discovery of Novel Nonpeptide Inhibitors Targeting SARS-CoV-2 M<SUP>pro</SUP>

Novel Alkynylamide-Based Nonpeptidic Allosteric Inhibitors for SARS-CoV-2 3-Chymotrypsin-like Protease

Discovery of 9,10-dihydrophenanthrene derivatives as SARS-CoV-2 3CLpro inhibitors for treating COVID-19

Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease

Discovery of Novel and Highly Potent Inhibitors of SARS CoV-2 Papain-Like Protease Through Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking, Molecular Dynamics Simulations, and Biological Evaluation

Naphthalen-1-ylethanamine-containing small molecule inhibitors of the papain-like protease of SARS-CoV-2

Design, Synthesis and Biological Evaluation of Novel 3C-Like Protease Inhibitors As Lead Compounds Against SARS-CoV-2.

Synthesis, X-Ray Crystallographic and Biological Activities of Covalent, Non-Peptidic Inhibitors of SARS-CoV-2 Main Protease

Identification of Novel SARS-CoV-2 3clpro Inhibitors by Molecular Docking, in Vitro Assays, Molecular Dynamics Simulations and DFT Analyses

Synthesis and biological evaluation of novel Peptidomimetic inhibitors of the coronavirus 3C-like protease

Discovery of 3-Phenyl-1,2,4-oxadiazole Derivatives As a New Class of SARS-CoV-2 Main Protease Inhibitors

Discovery of 3-Oxo-1,2,3,4-tetrahydropyrido[1,2-a]pyrazin Derivatives As SARS-CoV-2 Main Protease Inhibitors Through Virtual Screening and Biological Evaluation.

Peptide inhibitors derived from the nsp7 and nsp8 cofactors of nsp12 targeting different substrate binding sites of nsp12 of the SARS-CoV-2

De Novo Design of SARS-CoV-2 Main Protease Inhibitors with Characteristic Binding Modes

Antiviral Drug Design Based on Structural Insights into the N-terminal Domain and C-terminal Domain of the SARS-CoV-2 Nucleocapsid Protein

Discovery and structure-activity relationship studies of novel α-ketoamide derivatives targeting the SARS-CoV-2 main protease

Discovery of Polyphenolic Natural Products as SARS-CoV-2 Mpro Inhibitors for COVID-19

Dual-targeting Cyclic Peptides of Receptor-Binding Domain (RBD) and Main Protease (mpro) As Potential Drug Leads for the Treatment of SARS-CoV-2 Infection

Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2